about
Imaging and nanomedicine in inflammatory atherosclerosisPARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylationTelomere Length Maintenance and Cardio-Metabolic Disease Prevention Through Exercise Training.Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway.Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.The Role of Gut-brain Axis in Regulating Glucose Metabolism After Acute Pancreatitis.
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Common therapeutic targets in cardiometabolic disease
@ast
Common therapeutic targets in cardiometabolic disease
@en
Common therapeutic targets in cardiometabolic disease
@nl
type
label
Common therapeutic targets in cardiometabolic disease
@ast
Common therapeutic targets in cardiometabolic disease
@en
Common therapeutic targets in cardiometabolic disease
@nl
prefLabel
Common therapeutic targets in cardiometabolic disease
@ast
Common therapeutic targets in cardiometabolic disease
@en
Common therapeutic targets in cardiometabolic disease
@nl
P2860
P1476
Common therapeutic targets in cardiometabolic disease
@en
P2093
Gabrielle Fredman
P2860
P304
P356
10.1126/SCITRANSLMED.3008908
P407
P50
P577
2014-06-01T00:00:00Z